- Home
- BWFG vs RLMD Comparison
BWFG vs RLMD Comparison
Compare BWFG & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWFG | RLMD |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.4M | 515.2M |
| IPO Year | 2014 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BWFG | RLMD |
|---|---|---|
| Price | $66.73 | $4.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $55.00 | $12.40 |
| AVG Volume (30 Days) | 52.4K | ★ 1.2M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 261.79 | 45.28 |
| EPS | ★ 2.95 | N/A |
| Revenue | ★ $2,826,000.00 | $13,070.00 |
| Revenue This Year | $17.64 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | 43.96 | ★ 154.83 |
| 52 Week Low | $40.45 | $0.60 |
| 52 Week High | $69.59 | $8.00 |
Technical Indicators
Market Signals| Indicator | BWFG | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 34.01 |
| Support Level | $65.64 | $4.06 |
| Resistance Level | $69.41 | $4.97 |
| Average True Range (ATR) | 1.42 | 0.27 |
| MACD | -0.51 | 0.02 |
| Stochastic Oscillator | 38.39 | 20.41 |
Price Performance
Historical ComparisonAbout BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.